<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792490</url>
  </required_header>
  <id_info>
    <org_study_id>01742</org_study_id>
    <secondary_id>2017-003676-31</secondary_id>
    <secondary_id>01GM1704A</secondary_id>
    <secondary_id>01GM1704B</secondary_id>
    <secondary_id>00013948</secondary_id>
    <nct_id>NCT03792490</nct_id>
  </id_info>
  <brief_title>Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS</brief_title>
  <acronym>ROCK-ALS</acronym>
  <official_title>Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder and&#xD;
      therapeutic options are limited. The rho kinase (ROCK) inhibitor Fasudil was shown to be&#xD;
      neuroprotective, induced axonal regeneration and improved survival and behavioral outcome in&#xD;
      models of ALS and other neurodegenerative diseases. The aim of this phase IIa, multi-center&#xD;
      and double-blind study is to analyze the safety, tolerability and efficacy of fasudil in two&#xD;
      different doses compared to placebo in approximately 16 trial sites in Germany, France and&#xD;
      Switzerland. Intravenous application of fasudil will be performed in 80 patients and placebo&#xD;
      in 40 patients two times daily for 20 treatment days. The hypothesis is that fasudil is safe&#xD;
      and well-tolerated and its application will significantly improve the clinical outcome in&#xD;
      patients with ALS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (proportion of patients without treatment-related serious adverse events (SAE) up to day 180) and tolerability (proportion of patients without significant drug intolerance during the treatment period)</measure>
    <time_frame>From baseline (day 1) to last follow-up (day 180 ± 5)</time_frame>
    <description>Primary endpoint is the proportion of patients without significant drug intolerance during the treatment period (tolerability) and the proportion of patients without treatment-related serious adverse events (SAE) up to day 180 (safety).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30), second follow-up (day 90 ± 4), last follow-up (day 180 ± 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALS Functional Rating Scale (ALSFRS-R)</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30), second follow-up (day 90 ± 4), last follow-up (day 180 ± 5)</time_frame>
    <description>Amyotrophic lateral sclerosis functional rating scale - revised (ALSFRS-R):&#xD;
a scale to determine different aspects of functionality in patients with ALS, minimum 0 points, maximum 48 points, derived from a questionnaire with 12 questions, each of which can yield up to 4 points, higher score indicates better functionality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALS Assessment Questionnaire (ALSAQ-5)</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30), second follow-up (day 90 ± 4), last follow-up (day 180 ± 5)</time_frame>
    <description>Amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-5):&#xD;
a patient self-report five-item scale to determine the health status and quality of life in patients with ALS, higher scores show worse quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Cognitive and Behavioral ALS Screen (ECAS)</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30), second follow-up (day 90 ± 4), last follow-up (day 180 ± 5)</time_frame>
    <description>Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS):&#xD;
a scale to determine the cognitive function of patients with ALS, minimum 0 points, maximum 136 points, higher scores show better cognitive performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Unit Number Index (MUNIX)</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30), second follow-up (day 90 ± 4), last follow-up (day 180 ± 5)</time_frame>
    <description>Motor Unit Number Index (MUNIX):&#xD;
a neurophysiological method based on surface EMG recordings to estimate the number of motor units, higher scores indicate a higher number of motor units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>slow Vital capacity (VC)</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30), second follow-up (day 90 ± 4), last follow-up (day 180 ± 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (proportion of patients without treatment-related serious adverse events (SAE) up to end of treatment (day 26 to 30)) and tolerability (proportion of patients without significant drug intolerance during the treatment period)</measure>
    <time_frame>From baseline (day 1) to end of treatment (day 26 to 30)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fasudil 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasudil 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fasudil</intervention_name>
    <description>Fasudil hydrochloride hydrate IV solution</description>
    <arm_group_label>Fasudil 30 mg</arm_group_label>
    <arm_group_label>Fasudil 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Probable (clinically or laboratory) or definite ALS according to the revised version&#xD;
             of the El Escorial World Federation of Neurology criteria&#xD;
&#xD;
          -  Disease duration more than 6 months and less than 24 months (inclusive). Disease onset&#xD;
             defined as date of first muscle weakness, excluding fasciculations and cramps&#xD;
&#xD;
          -  Vital capacity more than 65% of normal (slow vital capacity; best of three&#xD;
             measurements)&#xD;
&#xD;
          -  Age: ≥ 18 years&#xD;
&#xD;
          -  Patients have to be treated with Riluzole (2 x 50mg/d), must be stable for at least&#xD;
             four weeks before randomization&#xD;
&#xD;
          -  Patients who have started on Edaravone therapy shall continue Edaravone treatment.&#xD;
             Edaravone treatment must not be discontinued for reasons of trial participation.&#xD;
&#xD;
          -  Women of childbearing age must be non-lactating and surgically sterile or using a&#xD;
             highly effective method of birth control and have a negative pregnancy test.&#xD;
             Acceptable methods of birth control with a low failure rate i.e. less than 1% per&#xD;
             year) when used consistently and correct are such as implants, injectables, combined&#xD;
             oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or&#xD;
             vasectomized partner&#xD;
&#xD;
          -  Capable of thoroughly understanding all information given and giving full informed&#xD;
             consent according to good clinical practice (GCP)&#xD;
&#xD;
          -  Patients have to have a valid health insurance, when recruited in a center in France&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in another clinical study involving trial medication within the&#xD;
             preceding 12 weeks or five terminal half times of the longest to be eliminated trial&#xD;
             medications (whichever is longer) or previous participation in this trial&#xD;
&#xD;
          -  Tracheostomy or continuous assisted ventilation of any type during the preceding three&#xD;
             months before randomization or a significant pulmonary disorder not attributed to ALS,&#xD;
             which may complicate the evaluation of respiratory function, intermittent non-invasive&#xD;
             ventilation is permitted,&#xD;
&#xD;
          -  Patients with a history of intracranial bleeding, known intracerebral aneurysms or&#xD;
             Moyamoya disease, or positive family history for the above. If only family history&#xD;
             positive, magnetic resonance (MR)- or x-ray-based cranial imaging not older than 24&#xD;
             months must confirm absence of bleeding, aneurysms or Moyamoya.&#xD;
&#xD;
          -  Gastrostomy&#xD;
&#xD;
          -  Any medical condition known to have an association with motor neuron dysfunction or&#xD;
             involving neuromuscular weakness or another neurodegenerative disease, e.g.&#xD;
             Parkinson's disease (PD) or Alzheimer's disease (AD), which might confound or obscure&#xD;
             the diagnosis of ALS&#xD;
&#xD;
          -  Presence of any concomitant life-threatening disease or impairment likely to interfere&#xD;
             with functional assessment&#xD;
&#xD;
          -  Patients with known arterial hypotension (resting blood pressure &lt;90/60 mmHg) or&#xD;
             previous hypotensive episodes or requiring treatment for increasing of blood pressure,&#xD;
             such as fludrocortisone, midodrine, etilefrine, cafedrine or theodrenaline&#xD;
&#xD;
          -  Patients with an uncontrollable or unstable arterial hypertensive disease (resting&#xD;
             blood pressure &gt;180 mmHg systolic and/or &gt;120 mmHg diastolic under current&#xD;
             antihypertensive medication)&#xD;
&#xD;
          -  Known pulmonary hypertension and any medication prescribed for treatment of pulmonary&#xD;
             hypertension&#xD;
&#xD;
          -  Confirmed hepatic insufficiency or abnormal liver function (stable aspartate&#xD;
             transaminase (ASAT) and/or alanine aminotransferase (ALAT) greater than 3 times the&#xD;
             upper limit of the normal range) and determined to be non-transient through repeat&#xD;
             testing&#xD;
&#xD;
          -  Renal insufficiency with a glomerular filtration rate (GFR) &lt;60 ml/min/1,73m²&#xD;
             (calculated by Modification of Diet in Renal Disease (MDRD) equation) and determined&#xD;
             to be non-transient through repeat testing&#xD;
&#xD;
          -  Major psychiatric disorder, significant cognitive impairment or clinically evident&#xD;
             dementia precluding evaluation of symptoms&#xD;
&#xD;
          -  Hypersensitivity to any component of the study drug&#xD;
&#xD;
          -  Liable to be not cooperative or comply with the trial requirements (as assessed by the&#xD;
             investigator), or unable to be reached in the case of emergency&#xD;
&#xD;
          -  Pregnant or breast-feeding females or females with childbearing potential, if no&#xD;
             adequate contraceptive measures are used&#xD;
&#xD;
          -  Prisoners or subjects who are involuntary incarcerated&#xD;
&#xD;
          -  Patients subject to legal protection measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Lingor, MD</last_name>
    <phone>+49 (0) 89 41408257</phone>
    <email>paul.lingor@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan C Koch, MD</last_name>
    <phone>+49 (0) 551 39 65628</phone>
    <email>jkoch@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahram Attarian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Camu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Hélène Soriani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Corcia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Meyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Günther, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan C Koch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Emmer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Petri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Grosskreutz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz Metelmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Lingor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Ludolph, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zeller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Weber, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://rock-als.uni-goettingen.de</url>
    <description>Information for patients and physicians</description>
  </link>
  <reference>
    <citation>Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC; ROCK-ALS Investigators. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol. 2019 Mar 27;10:293. doi: 10.3389/fneur.2019.00293. eCollection 2019.</citation>
    <PMID>30972018</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>December 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Paul Lingor</investigator_full_name>
    <investigator_title>International Coordinator</investigator_title>
  </responsible_party>
  <keyword>Motor neuron disease</keyword>
  <keyword>Neurodegenerative disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasudil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

